ArticleJournal of molecular neuroscience : MN2025
Cognitive and Behavioral Effects of Chronic Tartrazine Use in vivo: An Assessment Within and Above the Acceptable Daily Intake.
Article in Journal of molecular neuroscience : MN, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The use of dyes is a common practice in several industrial sectors to increase the attractiveness of the merchandise. Tartrazine is a synthetic yellow dye used in various food products; it contains an azo bond in its composition. The present study aimed to analyze whether the chronic consumption of Tartrazine promotes changes in cognitive and behavioral parameters in vivo. A total of 40 Wistar rats (50% male and 50% female) were divided into three experimental groups: control group (CG) (n = 16), group treated with a dose within the acceptable daily intake (ADI), corresponding to 7.5 mg/kg/day (NEG) (n = 16), and group treated above the recommended value at a dose of 15 mg/kg/day (AEG) (n = 8). Tartrazine was administered via gavage daily for 10 months. Finally, the rats were subjected to the open field test (OFT), elevated plus maze (EPM), and object recognition test (OR) to evaluate their motor activity, anxiety, and long-term memory, respectively. All data were subjected to statistical analysis using ANOVA or Kruskal-Wallis tests, with a significance level of 5% (p < 0.05). There were no statistically significant changes in locomotor behavior (p = 0.351) and anxiety levels (p = 0.305) of the animals in either group. However, the group treated within the ADI demonstrated impairment in long-term memory (p < 0.001). Given this, it can be considered that prolonged use of Tartrazine, even within the ADI value limits, can cause mild impairment of certain cognitive functions.
Indexed as
Identifiers
40968326What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.